Notice2025-19199
Prospective Grant of an Exclusive Patent License: Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
October 2, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Stage One Immunotherapeutics, Inc., incorporated in Delaware and with headquarters in Pennsylvania.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 189 (Thursday, October 2, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 189 (Thursday, October 2, 2025)]
[Notices]
[Pages 47782-47783]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-19199]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Patent License: Substituted
Quinoline Analogs As Aldehyde Dehydrogenase 1A1 Inhibitors
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Center for Advancing Translational Sciences, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an Exclusive Patent
License to practice the inventions embodied in the Patents and Patent
Applications listed in the SUPPLEMENTARY INFORMATION section of this
notice to Stage One Immunotherapeutics, Inc., incorporated in Delaware
and with headquarters in Pennsylvania.
DATES: Only written comments and/or applications for a license which
are received by the National Center for Advancing Translational
Sciences' Office of Strategic Alliances on or before October 17, 2025
will be considered.
ADDRESSES: Requests for copies of the patent or patent applications,
inquiries, and comments relating to the contemplated Exclusive Patent
License should be directed to: Rebecca Erwin-Cohen, Ph.D., Sr.
Technology Patenting and Licensing Specialist, NCATS Office of
Strategic Alliances, Telephone: 301.827.7235; Email: <a href="/cdn-cgi/l/email-protection#52203730373131337c3720253b3c7f313d3a373c123c3b3a7c353d24"><span class="__cf_email__" data-cfemail="beccdbdcdbdddddf90dbccc9d7d093ddd1d6dbd0fed0d7d690d9d1c8">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION:
Intellectual Property
``Substituted Quinoline Analogs As Aldehyde Dehydrogenase 1A1
Inhibitors''.
(1) U.S. Patent Application No. 17/682,654, filed on 28 Feb 2022
(HHS Res. No. E-101-2017-0-US-06), issued as Patent No. 11,795,177 on
24 October 2023, and
(2) European Patent Application EP22207287.8, filed on 14 November
2022 (HHS Res. No. E-101-2017-0-EP-07).
The patent rights in this invention have been assigned to the
Government of the United States of America.
The prospective exclusive license territory may be worldwide, and
the field of use may be limited to the following:
``Use of the Patent Rights to develop, manufacture, and
commercialize the Material (limited to compounds NCGC00588997,
NCGC00589125, NCGC00589163, and NCGC00589175) as a monotherapy, in
combinations, or in combination with an immunostimulator for the
treatment of hepatocellular carcinoma, renal cell carcinoma, and
pancreatic adenocarcinoma.''
This technology describes novel compounds that target Aldehyde
dehydrogenases (ALDHs); these enzymes are responsible for the
metabolism of aldehydes (both exogenous and endogenous). Overexpression
of certain ALDHs, especially ALDH1A1, in a number of malignancies and
cancer stem cells (CSCs) correlate with poor prognosis and tumor
aggressiveness, and are linked to drug resistance in traditional cancer
chemotherapy. Researchers from NCATS developed a novel series of newly
designed quinoline-based analogs of ALDH1A1 inhibitors with improved
enzymatic and cellular ALDH1A1 inhibition.
[[Page 47783]]
This Notice is made in accordance with 35 U.S.C. 209 and 37 CFR
404. The prospective exclusive license will be royalty bearing, and the
prospective exclusive license may be granted unless within fifteen (15)
days from the date of this published notice, the National Center for
Advancing Translational Sciences receives written evidence and argument
that establishes that the grant of the license would not be consistent
with the requirements of 35 U.S.C. 209 and 37 CFR 404.
Complete applications for a license that are timely filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive patent license. In response to this Notice,
the public may file comments or objections. Comments and objections,
other than those in the form of a license application, will not be
treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be
presumed to contain confidential business information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: September 26, 2025.
Joni Rutter,
Director, National Center for Advancing Translational Sciences,
National Institutes of Health.
[FR Doc. 2025-19199 Filed 10-1-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on October 2, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.